Sally Witherspoon, PhD: Learning from 360-Degree Feedback Custom Case Solution & Analysis
Evidence Brief: Sally Witherspoon Case Study
1. Financial Metrics
Department Performance: Sally Witherspoon leads the Clinical Research department, which has consistently met or exceeded all technical milestones and project deadlines over the last three years.
Compensation Structure: Performance bonuses for Sally and her team are tied 80 percent to project completion dates and 20 percent to internal quality metrics.
Turnover Costs: Two senior researchers resigned from Sally’s team in the previous 12 months. The estimated cost to replace a PhD-level researcher is 1.5 times their annual salary of 165,000 USD.
2. Operational Facts
Role: Director of Clinical Research at Gene-Pharmanex, a mid-sized biotechnology firm.
Headcount: Sally manages a team of 14 direct reports, including 9 PhD-level scientists and 5 administrative or technical support staff.
Reporting Line: Sally reports directly to Dr. Frank Richards, Vice President of Research and Development.
Feedback Mechanism: The 360-degree feedback process included 12 respondents: 1 supervisor, 4 peers, and 7 direct reports.
3. Stakeholder Positions
Sally Witherspoon: Views herself as a high-standard leader who drives excellence. Her self-assessment scores were in the top 10th percentile for leadership and communication.
Direct Reports: Categorized Sally as abrasive and micromanaging. Feedback scores for her empathy and developmental coaching were in the bottom 15th percentile.
Peers: Acknowledge her technical brilliance but report difficulty in cross-functional collaboration. Scores for team-player attributes were in the 30th percentile.
Dr. Frank Richards: Values Sally’s ability to deliver results but is concerned about the sustainability of her leadership style and the recent departures of key talent.
4. Information Gaps
Exit Interview Data: The case does not provide specific reasons cited by the two senior researchers who resigned.
Peer Performance: Comparative 360-degree data for other directors at Gene-Pharmanex is not available.
Client/External Feedback: There is no data regarding how external partners or regulatory bodies perceive Sally’s communication style.
Strategic Analysis
1. Core Strategic Question
Can Gene-Pharmanex retain Sally Witherspoon as a high-performing technical leader while forcing a behavioral shift to mitigate organizational friction and talent attrition?
Does the current performance management system over-index on technical output at the expense of leadership sustainability?
2. Structural Analysis
Applying the Emotional Intelligence Framework and Johari Window reveals a significant blind spot in Sally’s leadership profile. Her self-awareness is decoupled from her impact on others. The Situational Leadership model indicates that Sally employs a directing style regardless of the maturity or expertise of her PhD-level subordinates, leading to resentment and disengagement.
The structural problem is the Gene-Pharmanex culture, which has historically rewarded what is delivered over how it is delivered. This has created a protective shell around Sally, allowing her to ignore interpersonal deficiencies as long as clinical trials remained on schedule.
3. Strategic Options
Option
Rationale
Trade-offs
Resource Needs
Intensive Executive Coaching
Directly addresses the self-awareness gap through external intervention.
High cost; requires Sally to acknowledge the need for change.
External coach; 6 months of time.
Role Realignment
Moves Sally to a Chief Scientific Officer role with no direct reports.
Preserves technical genius but removes her from the leadership pipeline.
New Director of Clinical Research.
Performance-Linked Behavioral Mandate
Ties future bonuses and promotion eligibility to specific 360-degree score improvements.
Risk of Sally feeling targeted and leaving the firm.
HR monitoring and updated metrics.
4. Preliminary Recommendation
Gene-Pharmanex should pursue the Intensive Executive Coaching option combined with a revised performance contract. Sally is too valuable to lose but too toxic to leave unchanged. The coaching must focus on empathy and delegatory skills. Success will be measured by a follow-up 360-degree review in nine months. If scores do not improve by at least 30 percent in the bottom-quartile categories, she must be moved to an individual contributor role or exited from the firm.
Implementation Roadmap
1. Critical Path
Month 1: Debrief session between Sally, Frank Richards, and HR. Sally must formally acknowledge the feedback data.
Month 2: Selection and matching of an external executive coach specializing in technical-to-leadership transitions.
Month 2-6: Bi-weekly coaching sessions focused on active listening, delegation, and conflict resolution.
Month 3: Public acknowledgment by Sally to her team regarding the feedback and her commitment to specific behavioral changes.
Month 9: Administration of a pulse survey to the same 12 respondents to track progress.
2. Key Constraints
Ego Defense: Sally’s high self-rating suggests a strong psychological defense mechanism that may reject external feedback as inaccurate or biased.
Opportunity Cost: The time required for intensive coaching may distract Sally from critical clinical trial milestones in the short term.
Cultural Inertia: If the rest of the leadership team is not held to similar interpersonal standards, Sally will view this as a personal attack rather than a professional standard.
3. Risk-Adjusted Implementation Strategy
The plan assumes Sally is willing to change. To mitigate the risk of her departure, Gene-Pharmanex must simultaneously begin a confidential search for a potential successor. The coaching sessions should be framed as a prerequisite for her move to the next executive level, aligning the behavioral shift with her personal career ambitions. Contingency planning includes a technical fellow role if she fails the leadership transition but remains vital to the drug development pipeline.
Executive Review and BLUF
1. BLUF
Sally Witherspoon is a technical asset but a cultural liability. Her current leadership style is a primary driver of talent attrition and poses a long-term risk to the research and development pipeline. The firm can no longer trade interpersonal friction for technical punctuality. Gene-Pharmanex must implement a mandatory 6-month executive coaching program with explicit behavioral milestones. Failure to improve 360-degree scores by the end of the fiscal year must result in her removal from people management. The cost of replacing her is high, but the cost of a toxic department culture is higher.
2. Dangerous Assumption
The analysis assumes that Sally Witherspoon possesses the capacity for empathy and the psychological flexibility to change her personality traits. If her behavior is rooted in a fixed personality disorder rather than a lack of leadership training, coaching will fail regardless of the investment level.
3. Unaddressed Risks
Flight Risk: Sally may interpret the feedback and mandatory coaching as a lack of confidence from the VP of R&D and seek employment with a competitor, taking proprietary knowledge with her. (Probability: High; Consequence: Severe).
Team Cynicism: If Sally’s public apology is perceived as insincere or coerced by HR, it may further damage team morale and accelerate departures. (Probability: Medium; Consequence: Moderate).
4. Unconsidered Alternative
The team did not consider a structural team redesign where Sally retains her title but a Deputy Director is hired specifically to handle all people management and internal communication. This would allow Sally to focus exclusively on technical strategy while insulating the staff from her abrasive style. This creates a buffer that preserves her output while protecting the talent pool.